上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
15期
65-67
,共3页
肾功能不全%顺铂化疗%方案调整
腎功能不全%順鉑化療%方案調整
신공능불전%순박화료%방안조정
renal dysfunction%cisplatin%chemotherapy regimen adjustment
1例有高血压病史的74岁男性小细胞肺癌患者，首次依托泊苷联合顺铂姑息化疗后出现肾功能下降。临床药师认为，顺铂是导致患者肾功能下降的主要原因，建议将化疗方案更换为依托泊苷联合卡铂，并根据患者的肾功能情况将卡铂的目标 AUC 值定为5。患者化疗过程顺利。随访患者肾功能在第二次化疗后未出现进一步下降。
1例有高血壓病史的74歲男性小細胞肺癌患者，首次依託泊苷聯閤順鉑姑息化療後齣現腎功能下降。臨床藥師認為，順鉑是導緻患者腎功能下降的主要原因，建議將化療方案更換為依託泊苷聯閤卡鉑，併根據患者的腎功能情況將卡鉑的目標 AUC 值定為5。患者化療過程順利。隨訪患者腎功能在第二次化療後未齣現進一步下降。
1례유고혈압병사적74세남성소세포폐암환자，수차의탁박감연합순박고식화료후출현신공능하강。림상약사인위，순박시도치환자신공능하강적주요원인，건의장화료방안경환위의탁박감연합잡박，병근거환자적신공능정황장잡박적목표 AUC 치정위5。환자화료과정순리。수방환자신공능재제이차화료후미출현진일보하강。
A 74-year-old male small cell lung cancer patient with hypertension was treated with etoposide and cisplatin as the first line palliative chemotherapy. After the first cycle, the renal function of this patient was decreased. Clinical pharmacist recognized the cisplatin might be the primary cause for the renal dysfunction and advised to change chemotherapy regimen. The clinical application of chemotherapy in senior patients should be careful in order to reduce the incidence of renal injury and ensure drug safety. This pharmacist recommended to change chemotherapy into etoposide plus carboplatin and set the AUC at 5. The process of chemotherapy was successful. A further decline in renal function did not occur after the second chemotherapy according to the fellow-up.
